

DOI: 10.1002/open.201300024

Synthesis of the Tolerance-Inducing Oligosaccharide Lacto-*N*-Fucopentaose III Bearing an Activated Linker

Junfeng Zhang, Lu Zou, and Todd L. Lowary*^[a]

A concise synthetic route to an immunomodulatory pentasaccharide, lacto-*N*-fucopentaose III (**1**) and its corresponding human serum albumin conjugate, is described. Key transformations of the strategy include two highly regio- and stereoselec-

tive glycosylations for the construction of disaccharide **10** and pentasaccharide **12**, a Birch reduction for deprotection of benzyl ethers, and a UV-promoted radical addition of a thiol to an alkene for modification of the aglycone.

Introduction

Lacto-*N*-fucopentaose III (LNFPIII), a pentasaccharide containing the Lewis^x trisaccharide antigen, is an immunomodulatory glycan that is present on schistosome eggs.^[1] The expression of LNFPIII on schistosome eggs has been shown to suppress host immune responses, which enables the parasite to escape detection of the mammalian host immune system thus facilitating survival.^[1] LNFPIII is also found in breast milk and the urine of pregnant women, as well as the fetal brain, and has been speculated to have a similar protective immunomodulatory effect in the fetus.^[1,2] Recently, Burlingham and co-workers demonstrated that a LNFPIII conjugate can prolong allogeneic graft survival in neonatal heart transplantation models.^[3] Although the biological role LNFPIII plays in graft prolongation remains to be further investigated, a preliminary mechanistic study suggested that the LNFPIII conjugate significantly upregulated the expression of programmed death ligand 1,^[3] which negatively regulates immune responses through binding with its receptor, programmed cell death protein 1, expressed on the surface of activated T cells, B cells and macrophages.^[4] This observation suggests that LNFPIII is a potential tolerance-inducing oligosaccharide.

We have been interested in accessing devices (nanoparticles or stents) carrying synthetic ABO blood group antigens and tolerance-inducing glycans for use in inducing specific B-cell tolerance during immune development, with the aim to extend the window for ABO-incompatible heart transplants.^[5] As part of this program, we wanted to determine if LNFPIII presented together with the ABO blood group structures could

promote immune tolerance to these antigens in neonates. Carrying out these studies required access to milligram quantities of LNFPIII functionalized with a linker that would allow its attachment to surfaces, for example, proteins as well as amine-coated nanoparticles or stents.^[6] Although previous synthesis of LNFPIII derivatives have been reported by Sinaý^[7] and Zhang,^[8] none of these compounds was suitably functionalized for our purposes. We describe here the synthesis of LNFPIII bearing an activated ester moiety in the aglycone **1** (Figure 1) and its corresponding human serum albumin (HSA) conjugate.

Results and Discussion

We envisioned (Scheme 1) constructing pentasaccharide **1** from four readily available carbohydrates, D-galactose, L-fucose, *N*-acetyl-D-glucosamine and lactose, via trisaccharide thioglycoside **2** and disaccharide diol **3**. An important feature was a regio- and stereoselective [3+2] glycosylation, a key strategy in earlier routes to LNFPIII derivatives,^[7,8] followed by global deprotection and introduction of the activated ester. Thioglycoside **2** can be assembled through regioselective condensation of trichloroacetimidate **4** with diol **6** followed by treatment of the product with thioglycoside **5**.

As illustrated in Scheme 2, diol **3** was prepared from lactose. First, acetylation was performed in acetic anhydride at 100 °C in the presence of sodium acetate to form preferentially the β anomer of lactose heptaacetate (α/β = 1:5). This compound was then coupled with 7-octen-1-ol using boron trifluoride diethyl etherate as the promoter to generate octenyl glycoside **7** in 43% overall yield. The ¹H NMR spectrum of **7** showed the anomeric proton H-1 at 4.45 ppm as a doublet with a coupling constant between H-1 and H-2 of 8.0 Hz, indicating the newly formed glycosidic linkage was β. Then, deacetylation of **7** using a catalytic amount of sodium methoxide afforded **8** in 92% yield. Finally, installation of an isopropylidene ketal at the 3'- and 4'-positions of **8**, benzylation of the remaining five hydroxyl groups, followed by acid hydrolysis of the isopropylidene ketal enabled the conversion of **8** to diol **3** in 63% yield over three steps.^[9] To access diol **6**, previously reported com-

[a] J. Zhang, L. Zou, T. L. Lowary
Alberta Glycomics Centre and Department of Chemistry
University of Alberta, Gunning-Lemieux Chemistry Centre
Edmonton, AB T6G 2G2 (Canada)
E-mail: tlowary@ualberta.ca

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/open.201300024>.

© 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.






Figure 1. Structure of LNPFI1 1 with activated flexible linker.



Scheme 1. Retrosynthetic analysis of 1. Bn = benzyl; Phth = phthaloyl; Tol = tolyl.



Scheme 2. Synthesis of building blocks A) 3 and B) 6. Reagents and conditions: a) Ac_2O , NaOAc , 100°C , 79%; b) $\text{BF}_3\cdot\text{Et}_2\text{O}$, 7-octen-1-ol, CH_2Cl_2 , 43%; c) NaOMe , 1:3 v/v $\text{CH}_2\text{Cl}_2/\text{MeOH}$, RT, overnight, 92%; d) $(\text{CH}_3)_2\text{C}(\text{OCH}_3)_2$, *p*-TsOH, DMF, 85°C , 1.5 h; e) NaH (6.6 equiv), BnBr (8.3 equiv), DMF, $0^\circ\text{C} \rightarrow \text{RT}$; f) 4:1 v/v $\text{AcOH}/\text{H}_2\text{O}$, 80°C , 3 h, 63% over three steps; g) $\text{BH}_3\cdot\text{NMe}_3$ (4.0 equiv), AlCl_3 (6.0 equiv), THF, RT, 3 h, 83%.

compound 9^[10] underwent regioselective reductive opening of the benzylidene ring using $\text{BH}_3\cdot\text{NMe}_3$ and AlCl_3 ^[11] to the desired compound in 82% yield. Building blocks 4^[12] and 5^[10] and were synthesized according to previous reports.


With 3–6 in hand, the construction of the pentasaccharide was carried out (Scheme 3). First, trichloroacetimidate 4 was coupled with diol 6 in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) to generate regioselectively the β -(1→4)-linked disaccharide 10 in 70% yield. The β stereochemistry was confirmed

from the H-1, H-2 coupling constant of the galactopyranosyl residue ($^3J_{\text{H-1,H-2}} = 8.0 \text{ Hz}$). The regioselectivity of the glycosylation was determined by a 2D NMR experiment. In the HMBC spectrum of 10, the expected correlations between H-1_{Gal} and C-4_{GlcNAc}, H-4_{GlcNAc} and C-1_{Gal} are both observed, while correlations between H-1_{Gal} and C-3_{GlcNAc}, H-3_{GlcNAc} and C-1_{Gal} are not, indicating that the newly formed glycosidic linkage is the desired β -(1→4)-linked disaccharide instead of the β -(1→3)-

linked isomer. The regioselectivity of this glycosylation can be rationalized by matched–mismatched glycosylation.^[13,14] In this case, disarmed donor 4 reacts preferentially with the less reactive C-4 hydroxyl group in diol 6. In addition, the steric effect induced by the *N*-phthalimido group at C-2 position also likely contributes to the regioselectivity.^[13]


The fucosylation of disaccharide 10 with thioglycoside 5 in toluene using *N*-iodosuccinimide (NIS) and silver triflate (AgOTf) as the catalyst provided trisaccharide 2 in 75% yield with excellent stereoselectivity. The anomeric proton of the fucopyranoside residue in 10 appeared around 4.84 ppm, overlapping with a methylene proton from the benzyl groups. Therefore, the one-bond heteronuclear coupling constant at the anomeric centre of the fucose residue ($^1J_{\text{C-1,H-1}}$)^[15] was used to determine the stereochemistry at the newly formed linkage; the value is 170.3 Hz, which unambiguously confirms the α stereochemistry of this residue. The armed nature of 5 relative to 10^[10] allows this reaction to proceed efficiently without competing activation of the disaccharide acceptor or trisaccharide product.

The final planned glycosylation reaction, coupling of trisaccharide 2 and diol 3, cannot be carried out using NIS and AgOTf activation because of incompatibility of these conditions with the alkene functionality in the aglycone. To circumvent this problem, an alternative promoter system using diphenylsulfoxide in combination with triflic anhydride^[16] was explored, but the desired product was obtained in low yield. Al-



Scheme 3. Synthesis of protected pentasaccharide **12**. *Reagents and conditions:* a) TMSOTf, CH₂Cl₂, -40 °C, 2 h 70%; b) **5** (2.5 equiv), NIS (2.4 equiv), AgOTf (0.24 equiv), toluene, 0 °C, 75%; c) NBS (2.5 equiv), 9:1 v/v acetone/H₂O, 0 °C, 0.5 h, 80%; d) DBU, Cl₃CCN (7.0 equiv), CH₂Cl₂, RT, 4 h; e) **3** (1.3 equiv), TMSOTf, CH₂Cl₂, -20 °C, 49% over two steps; f) Ac₂O, pyridine, RT, overnight, 93%.

though other thioglycoside activation conditions, for example using dimethylthiosulfonium triflate could have been explored, we chose instead to convert **2** into an alternate glycosyl donor. Therefore, thioglycoside **2** was treated with *N*-bromosuccinimide (NBS) in acetone/water (9:1 v/v) to afford hemiacetal **11** in 80% yield. This compound was subsequently converted to corresponding trichloroacetimidate by treatment with trichloroacetoneitrile in the presence of catalytic amount of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The freshly made donor was then used in a reaction with diol acceptor **3** to give the pentasaccharide **12** in 49% yield over two steps. The β stereochemistry of the newly formed linkage was established based on the $^3J_{H-1,H-2}$ (8.5 Hz) and $^1J_{C-1,H-1}$ (165.5 Hz) values. To confirm the regioselectivity, a small amount of pentasaccharide **12** was acetylated to generate **12'**. Upon comparison of 1H NMR spectra of these two compounds, a broad signal at 4.05 ppm in **12** shifted to 5.46 ppm in **12'** and appeared as a doublet of doublets ($J=3.6$ and 0.6 Hz). The values of these coupling constants indicated that the acetyl group was introduced onto O-4' of the lactose moiety, confirming that the newly introduced glycosidic linkage was β -(1 \rightarrow 3) not β -(1 \rightarrow 4).



Scheme 4. Synthesis of PNP ester **1**. *Reagents and conditions:* a) Ethylenediamine, *n*-butanol, 100 °C, 20 h; b) 1:2 v/v CH₂Cl₂/MeOH, Ac₂O, Et₃N, 83% over two steps; c) Na, NH₃, -78 °C, 2 h, 97%; d) cysteamine-HCl (10.0 equiv), MeOH, UV, 2.5 h, quantitative; e) HO⁻ resin, MeOH; f) concentration; g) *N,N*-dimethylacetamide, di-*p*-nitrophenyl adipate (5.0 equiv), 83%.

verted to free amine by exchange with HO⁻ resin, followed by coupling with di-*p*-nitrophenyl adipate^[18] in dimethylacetamide to yield the desired highly reactive *p*-nitrophenol (PNP) ester **1** in 83% overall yield. Conversion of **1** into the corresponding human serum albumin (HSA) conjugate was then done by treatment of HSA with **1** in phosphate buffer (pH 7.5). The MALDI-MS spectrum of the resulting glycoconjugate showed two peaks, one centred around $m/z=45693$ and another at $m/z=91377$, corresponding to the +2 and +1 charge states

With the pentasaccharide assembled, treatment of **12** with ethylenediamine in *n*-butanol at 100 °C for 20 h (Scheme 4), followed by selective *N*-acetylation, led to formation of **13**. Birch reduction was conducted to remove the benzyl groups, while keeping intact the alkene functionality for further modification. The fully unprotected pentasaccharide **14** was obtained in 97% yield. A UV-promoted radical addition of a thiol to the alkene^[17] was then performed to further functionalize the octenyl linker with a cysteamine residue, leading to corresponding amine salt **15** in quantitative yield. Finally, the amine salt was con-

of the protein, respectively, both bound to 21 pentasaccharide units.

Conclusions

In conclusion, we have achieved the synthesis of LNPFIII functionalized with reactive *p*-nitrophenol ester (PNP) and the corresponding human serum albumin (HSA) conjugate. The synthetic strategy features two highly regio- and stereoselective glycosylations for the construction of disaccharide **10** and pentasaccharide **12** based on the reactivity difference between two hydroxyl groups in acceptor **6** and **3**, respectively. Birch reduction enabled the deprotection of benzyl ethers while leaving the octenyl linker intact, which allowed further functionalization to form PNP ester **1** and, in turn, the HSA conjugate. Studies on the use of this HSA conjugate in animal models of graft survival are ongoing.

Experimental Section

General: All reagents were purchased from commercial sources and were used without further purification unless noted. Dry solvents used in reactions were purified by successive passage through columns of alumina and copper under an argon atmosphere. All reactions were carried out under a positive pressure of argon unless otherwise stated, monitored by TLC on silica gel 60 F₂₅₄ (0.25 mm; Silicycle, Quebec, Canada), and the spots were visualized under UV light (254 nm) and/or stained by charring with acidified anisaldehyde solution in EtOH. Column chromatography was performed on silica gel 60 (40–60 μm) or C₁₈ silica gel (35–70 μm, Toronto Research Chemicals). ¹H NMR spectra were recorded at 500 or 600 MHz, and chemical shifts were referenced to CHCl₃ (7.26 ppm, CDCl₃), CD₂HOD (3.31 ppm CD₃OD), or HOD (4.79 ppm, D₂O). ¹³C NMR spectra were recorded at 126 MHz and chemical shifts were referenced to CDCl₃ (77.06 ppm, CDCl₃), CD₃OD (49.0 ppm, CD₃OD) or external acetone (31.07 ppm, D₂O). Assignments of NMR spectra were made on the basis of 2D experiments (¹H–¹H COSY, HSQC and HMBC), and the stereochemistry of the newly formed glycosidic linkages was confirmed by measuring ¹J_{C–1,H–1} values using an ¹H-coupled HSQC experiment. In the data provided below, the resonances on particular residues are indicated by an increasing number of primes (′) moving from the reducing to nonreducing end. For example, in **15** H-1 is H-1 of the Glc residue, H-1′ is H-1 of the GlcNAc residue, and H-1″ is H-1 of the Fuc residue. Electrospray ionization mass spectra were recorded on an Agilent Technologies 6220 TOF spectrometer on samples dissolved in CH₂Cl₂ or MeOH. MALDI mass spectra were obtained in the linear positive mode of ionization on a Bruker Daltonics (Bremen, GmbH) UltrafleXtreme MALDI TOF/TOF mass spectrometer using sinapinic acid as the matrix. Optical rotations were measured on PerkinElmer 241 polarimeter at 22 ± 2 °C in units of degree mL/(g dm).

6-[[[2-[[8-(β-D-galactopyranosyl-(1→4)-[α-L-fucopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→3)]-β-D-galactopyranosyl-(1→4)]-β-D-glucopyranosyl-oxy]octyl]thio]ethyl]amino]-6-oxo-hexanoic acid *p*-nitrophenyl ester (1**):** Compound **15** (10 mg, 9.3 μmol) was dissolved in MeOH (5 mL) and treated with Amberlite IR400 HO[−] ion-exchange resin to convert the hydrochloride salt to the free amine. The solution was filtered, concentrated and dried overnight in vacuo. The residue was dissolved in *N,N*-di-

methylacetamide (0.5 mL) and treated with di-*p*-nitrophenyl adipate (18 mg, 46.4 μmol). After stirring at RT for 4 h, the solution was concentrated in vacuo to dryness. The residue was subjected to C₁₈ chromatography using gradient elution (0.5% aq AcOH → MeOH/0.5% aq AcOH (60:40 v/v) to give **1** as a white foam after lyophilization (10 mg, 83%): ¹H NMR (600 MHz, CD₃OD): δ = 8.29 (d, *J* = 9.2 Hz, 2H, Ar), 7.37 (d, *J* = 9.2 Hz, 2H, Ar), 5.05 (d, *J* = 4.0 Hz, 1H, H-1″), 4.83–4.82 (m, 1H, H-5″), 4.69 (d, *J* = 8.1 Hz, 1H, H-1′), 4.43 (d, *J* = 7.6 Hz, 1H, one of H-1, H-1′, H-1″), 4.36 (d, *J* = 7.7 Hz, 1H, one of H-1, H-1′, H-1″), 4.27 (d, *J* = 7.8 Hz, 1H, one of H-1, H-1′, H-1″), 4.04 (d, *J* = 3.0 Hz, 1H), 3.95 (dd, *J* = 6.3, 3.3 Hz, 1H), 3.92–3.81 (m, 8H), 3.79–3.75 (m, 3H), 3.71–3.49 (m, 12H), 3.46–3.41 (m, 3H), 3.39–3.36 (m, 1H), 3.35 (t, *J* = 7.0 Hz, 2H, SCH₂CH₂N), 3.22 (dd, *J* = 9.1, 7.9 Hz, 1H), 2.66 (t, *J* = 7.1 Hz, 2H, OC(O)CH₂), 2.62 (t, *J* = 7.0 Hz, 2H, SCH₂CH₂N), 2.53 (t, *J* = 7.3 Hz, 2H, SCH₂(CH₂)₆CH₂O), 2.25 (t, *J* = 7.0 Hz, 2H, NHC(O)CH₂), 1.97 (s, 3H, NHAc), 1.77–1.73 (m, 4H, NC(O)CH₂(CH₂)₂CH₂C(O)O), 1.61–1.55 (m, 4H, OCH₂CH₂-(CH₂)₄CH₂CH₂S), 1.39–1.30 (m, 8H, OCH₂CH₂(CH₂)₄CH₂CH₂S), 1.17 ppm (d, *J* = 6.6 Hz, 3H, H-6″); ¹³C NMR (126 MHz, CD₃OD): δ = 174.3 (C=O), 173.1 (C=O), 171.2 (C=O), 155.7 (Ar), 145.4 (Ar), 124.7 (2C, Ar), 122.5 (2C, Ar), 103.6, 102.8, 102.5 (C-1, C-1′, C-1″), 102.4 (C-1′), 98.8 (C-1″), 82.4, 79.1, 75.8, 75.3, 75.2, 75.1, 75.02, 74.99, 73.5 (2C), 73.3, 72.3, 71.4, 70.1, 69.8, 69.5 (OCH₂(CH₂)₆CH₂S), 68.6 (2C), 68.4, 66.3 (C-5″), 61.4, 61.0, 60.5, 59.8 (C-6, C-6′, C-6″, C-6″), 56.3 (C-2″), 38.7 (SCH₂CH₂N), 35.2 (NHC(O)CH₂), 33.2 (OC(O)CH₂), 31.2 (SCH₂CH₂N), 30.8 (SCH₂(CH₂)₆CH₂O), 29.3 (2C), 29.0, 28.8, 28.4 (5 × SCH₂(CH₂)₆CH₂O), 25.6, 24.8, 23.8 (SCH₂(CH₂)₆CH₂O, 2 × NC(O)CH₂(CH₂)₂CH₂C(O)O), 21.8 (NHAc), 15.2 ppm (C-6″); HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₅₄H₈₇N₃NaO₃₀S: 1312.4987, found: 1312.4986.

***p*-Tolyl 2,3,4,6-tetra-*O*-acetyl-β-D-galactopyranosyl-(1→4)-[2,3,4-tri-*O*-benzyl-α-L-fucopyranosyl-(1→3)]-6-*O*-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (**2**):** A mixture of thioglycoside **5** (2.74 g, 5.07 mmol), acceptor **10** (1.70 g, 2.03 mmol) and powdered 4 Å molecular sieves was suspended in toluene (30 mL) and stirred at RT for 1 h. The solution was cooled to 0 °C, and *N*-iodosuccinimide (1.10 g, 4.88 mmol) and silver trifluoromethanesulfonate (125 mg, 0.49 mmol) were added. After stirring at 0 °C for 2 h, Et₃N (1 mL) was added, and the mixture was filtered through Celite. The filtrate was concentrated, and the resulting residue was subjected to flash chromatography (2:1 v/v hexane/EtOAc) to afford trisaccharide **2** as a white foam (1.90 g, 75%): *R*_f = 0.24 (2:1 v/v hexane/EtOAc); [α]_D = +7.1 (c = 0.9, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ = 7.75–7.70 (m, 4H, Ar), 7.45–7.01 (m, 24H, Ar), 5.44 (d, *J* = 10.5 Hz, 1H, H-1), 5.26 (dd, *J* = 3.5, 1.0 Hz, 1H, H-4′), 5.04 (dd, *J* = 10.4, 8.2 Hz, 1H, H-2′), 4.84–4.79 (m, 4H, H-1″, H-3′, 2 × OCH₂Ph), 4.77–4.72 (m, 2H, H-1′, H-3), 4.65–4.60 (m, 3H, H-5″, 2 × OCH₂Ph), 4.58 (A of ABq, *J* = 11.7 Hz, 1H, OCH₂Ph), 4.53–4.48 (m, 2H, H-2, OCH₂Ph), 4.46, 4.28 (ABq, *J* = 12.3 Hz, 2H, 2 × OCH₂Ph), 4.18–4.13 (m, 2H, H-4, H-6a′), 3.98 (dd, *J* = 10.7, 5.7 Hz, 1H, H-6b′), 3.92–3.88 (m, 2H, H-3″, H-6a), 3.85–3.80 (m, 2H, H-2″, H-6b) 3.64 (d, *J* = 1.3 Hz, 1H, H-4″), 3.57–3.55 (m, 2H, H-5, H-5′), 2.29 (s, 3H, ArMe), 2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.86 (s, 3H, OAc), 1.21 ppm (d, *J* = 6.5 Hz, 3H, H-6″); ¹³C NMR (126 MHz, CDCl₃): δ 170.0 (C=O), 169.8 (C=O), 168.7 (C=O), 138.9 (Ar), 138.7 (Ar), 138.2 (Ar), 138.1 (Ar), 137.9 (Ar), 134.2 (Ar), 133.3 (Ar), 131.8 (Ar), 129.6 (Ar), 128.6 (Ar), 128.3 (Ar), 128.24 (Ar), 128.17 (Ar), 128.1 (Ar), 128.02 (Ar), 127.97 (Ar), 127.86 (Ar), 127.4 (Ar), 127.2 (Ar), 127.1 (Ar), 127.0 (Ar), 123.7 (Ar), 99.5 (C-1′), 97.6 (C-1″), 84.4 (C-1), 79.8 (C-3″), 79.6 (C-5), 77.2 (C-4″), 75.0 (C-4), 74.5 (C-2″) 74.2 (OCH₂Ph), 73.64 (C-3), 73.58, 73.0, 72.3 (3 × OCH₂Ph), 71.0 (C-3′), 70.4 (C-5′), 69.0 (C-2′), 67.85 (C-6), 66.76 (C-4′), 66.5 (C-5″), 60.2 (C-6′), 55.6 (C-2), 21.1, 20.7, 20.62, 20.55, 20.54 ppm (4 × OAc, ArMe); 16.7 (C-6″); HRMS

(ESI): m/z $[M+Na]^+$ calcd for $C_{69}H_{73}NNaO_{19}S$: 1274.4390, found: 1274.4385.

7-Octen-1-yl 2,6-di-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (3): NaOMe (1.0 M, 2.7 mL) was added to a solution of **7** (2.89 g, 3.87 mmol) in CH_2Cl_2 /MeOH (1:3 v/v, 40 mL). After stirring at RT overnight, the solution was neutralized with Amberlite IR120 H^+ ion-exchange resin. The solution was filtered and the filtrate was concentrated to afford **8** as a white solid (1.61 g, 92%). A portion of **8** (1.65 g, 3.65 mmol) and *p*-TsOH (41 mg) were suspended in a mixture of dry *N,N*-dimethylformamide (DMF; 8 mL) and 2,2-dimethoxypropane (24 mL). After stirring at 85 °C for 1.5 h, the solution was cooled to RT, neutralized with Et_3N (1 mL), concentrated in vacuo and dried. The resulting residue and BnBr (2.9 mL, 24.3 mmol) were dissolved in dry DMF (40 mL), to which NaH (60%, 1.22 g, 30.5 mmol) was added in portions at 0 °C, followed by vigorous stirring. After stirring overnight at RT, MeOH (4 mL) was added. The solution was concentrated in vacuo, dissolved in EtOAc (200 mL) and washed with H_2O and brine. The organic layer was dried over Na_2SO_4 , filtered and concentrated to dryness. Subsequently, the obtained crude residue was treated with 80% aq HOAc (160 mL) at 80 °C for 3 h. The solution was concentrated, dissolved in EtOAc (200 mL) and washed with saturated aq $NaHCO_3$, H_2O and brine. The organic layer was dried over Na_2SO_4 , filtered, concentrated and the residue subjected to flash chromatography (5:2 v/v hexane/EtOAc) to afford diol **3** as a white solid (2.07 g, 63% over three steps): $R_f=0.40$ (2:1 v/v hexane/EtOAc); $[\alpha]_D^{20} = +16.4$ ($c=0.9$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$): $\delta = 7.39$ – 7.22 (m, 25H, Ar), 5.81 (ddt, $J = 17.0$, 10.3, 6.7 Hz, 1H, $CH=CH_2$), 5.02–4.92 (m, 3H, $CH=CH_2$, OCH_2Ph), 4.91, 4.72 (ABq, $J = 11.0$ Hz, 2H, $2 \times OCH_2Ph$), 4.82, 4.68 (ABq, $J = 11.5$ Hz, 2H, $2 \times OCH_2Ph$), 4.79 (A of ABq, $J = 11.0$ Hz, 1H, OCH_2Ph), 4.61 (A of ABq, $J = 12.5$ Hz, 1H, OCH_2Ph), 4.47–4.44 (m, 3H, H-1', $2 \times OCH_2Ph$), 4.41–4.38 (m, 2H, H-1, OCH_2Ph), 3.99 (app t, $J = 9.5$ Hz, 1H, H-4), 3.97–3.92 (m, 2H, H-4', octenyl OCH_2), 3.82 (dd, $J = 11.0$, 4.0 Hz, 1H, H-6a), 3.77 (dd, $J = 11.0$, 2.0 Hz, 1H, H-6b), 3.64–3.58 (m, 2H, H-3, H-6a'), 3.54–3.49 (m, 2H, H-6b', octenyl OCH_2), 3.45–3.39 (m, 4H, H-2, H-2', H-3', H-5), 3.37–3.35 (m, 1H, H-5'), 2.48 (d, $J = 3.5$ Hz, 1H, 4'-OH), 2.41 (d, $J = 4.0$ Hz, 1H, 3'-OH), 2.06–2.02 (m, 2H, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$), 1.69–1.62 (m, 2H, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$), 1.45–1.31 ppm (m, 6H, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$); ^{13}C NMR (126 MHz, $CDCl_3$): $\delta = 139.2$ (Ar), 139.1 ($CH=CH_2$), 138.7 (Ar), 138.4 (Ar), 138.3 (Ar), 138.0 (Ar), 128.5 (Ar), 128.4 (Ar), 128.32 (Ar), 128.30 (Ar), 128.08 (Ar), 128.06 (Ar), 128.0 (Ar), 127.93 (Ar), 127.86 (Ar), 127.7 (Ar), 127.6 (Ar), 127.57 (Ar), 127.54 (Ar), 127.3 (Ar), 114.3 ($CH=CH_2$), 103.7 (C-1), 102.6 (C-1'), 82.9 (C-3), 81.8, 80.1 (C-2, C-2'), 76.7 (C-4), 75.2 (OCH_2Ph), 75.1 (C-5), 74.93, 74.90 ($2 \times OCH_2Ph$), 73.6 (C-3'), 73.5, 73.2 ($2 \times OCH_2Ph$), 72.9 (C-5'), 70.0 (octenyl OCH_2), 68.8 (C-4'), 68.7 (C-6'), 68.4 (C-6), 33.8, 29.7, 29.0, 28.9, 26.1 ppm ($5 \times$ octenyl CH_2); HRMS (ESI): m/z $[M+Na]^+$ calcd for $C_{55}H_{66}NaO_{11}$: 925.4497, found: 925.4489.

p-Tolyl 6-O-benzyl-2-deoxy-2-phthalimido-1-thio- β -D-glucopyranoside (6): Benzylidene acetal **9** (1.82 g, 3.62 mmol) and $BH_3 \cdot NMe_3$ (1.06 g, 14.50 mmol) were dissolved in THF (26 mL) and cooled to 0 °C, then an ice-cold solution of $AlCl_3$ (2.90 g, 21.74 mmol) in THF (10 mL) was added. After stirring at RT for 3 h, the solution was concentrated, dissolved in EtOAc (200 mL) and washed with saturated aq $NaHCO_3$, H_2O and brine. The organic layer was dried over Na_2SO_4 , filtered, concentrated and subjected to flash chromatography (hexane/EtOAc 3:4 v/v) to afford diol **6** as a white solid (1.50 g, 82%): $R_f=0.29$ (3:4 v/v hexane/EtOAc); $[\alpha]_D^{20} = +16.3$ ($c=1.0$, $CHCl_3$); 1H NMR (500 MHz; $CDCl_3$): $\delta = 7.87$ – 7.85 (m, 2H, Ar), 7.75–7.74 (m, 2H, Ar), 7.40–7.29 (m, 7H, Ar), 7.04–7.02 (m,

2H, Ar), 5.56 (d, $J = 10.3$ Hz, 1H, H-1), 4.63, 4.58 (ABq, $J = 11.4$ Hz, 2H, $2 \times OCH_2Ph$), 4.35 (dd, $J = 10.3$, 8.3 Hz, 1H, H-3), 4.21 (app t, $J = 10.3$ Hz, 1H, H-2), 3.85 (dd, $J = 10.5$, 4.5 Hz, 1H, H-6a), 3.81 (dd, $J = 10.5$, 4.5 Hz, 1H, H-6b), 3.68–3.60 (m, 2H, H-4, H-5), 2.30 ppm (s, 3H, OAc); ^{13}C NMR (126 MHz; $CDCl_3$): $\delta = 138.2$ (Ar), 137.7 (Ar), 134.2 (Ar), 133.3 (Ar), 131.7 (Ar), 129.6 (Ar), 128.5 (Ar), 128.2 (Ar), 127.9 (Ar), 127.8 (Ar), 83.8 (C-1), 77.8 (C-5), 73.8 (OCH_2Ph), 73.6 (C-4), 72.8 (C-3), 70.5 (C-6), 55.4 (C-2), 21.1 ppm (ArMe); HRMS (ESI): m/z $[M+Na]^+$ calcd for $C_{28}H_{27}NNaO_6S$: 528.1451, found: 528.1451.

7-Octen-1-yl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (7): D -Lactose (10.00 g, 29.2 mmol) and NaOAc (2.5 g, 30.5 mmol) were heated in Ac_2O (80 mL) at 100 °C for 5 h. The solution was allowed to cool to RT and poured into ice water (1 L). The precipitate was filtered and recrystallized from EtOAc/hexane to yield peracetylated lactose as colourless crystals (15.60 g, 79%). A portion of this compound (6.78 g, 10 mmol), 7-octen-1-ol (2.4 mL, 16 mmol) and 4 Å molecular sieves was dissolved in CH_2Cl_2 (80 mL) and stirred at RT for 0.5 h. The solution was cooled to 0 °C, and $BF_3 \cdot Et_2O$ (3.8 mL, 30 mmol) was added. After stirring at RT for 24 h, Et_3N (5 mL) was added, and the reaction mixture was filtered through Celite. The filtrate was concentrated and the residue was subjected to flash chromatography (4:3 v/v hexane/EtOAc) to afford **7** as white foam (3.2 g, 43%): $R_f=0.39$ (1:1 v/v hexane/EtOAc); $[\alpha]_D^{20} = -11.6$ ($c=1.1$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$): $\delta = 5.79$ (ddt, $J = 17.0$, 10.3, 6.7 Hz, 1H, $CH=CH_2$), 5.34 (dd, $J = 3.4$, 1.1 Hz, 1H, H-4'), 5.19 (app t, $J = 9.5$ Hz, 1H, H-3), 5.10 (dd, $J = 10.4$, 7.9 Hz, 1H, H-2'), 5.01–4.91 (m, 3H, $CH=CH_2$, H-3'), 4.88 (dd, $J = 9.5$, 8.0 Hz, 1H, H-2), 4.49–4.46 (m, 2H, H-1', H-6a), 4.45 (d, $J = 8.0$ Hz, 1H, H-1), 4.15–4.06 (m, 3H, H-6b, H-6a', H-6b'), 3.88–3.85 (m, 1H, H-5'), 3.82 (dt, $J = 9.7$, 6.8 Hz, 1H, octenyl OCH_2), 3.79 (app t, $J = 9.5$ Hz, 1H, H-4), 3.59 (ddd, $J = 9.9$, 5.1, 2.1 Hz, 1H, H-5), 3.44 (dt, $J = 9.7$, 6.8 Hz, 1H, octenyl OCH_2), 2.15 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.06–2.03 (m, 14H, $4 \times OAc$, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$), 1.96 (s, 3H, OAc), 1.57–1.51 (m, 2H, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$), 1.39–1.25 ppm (m, 6H, $OCH_2CH_2(CH_2)_3CH_2CH=CH_2$); ^{13}C NMR (126 MHz, $CDCl_3$): $\delta = 170.4$ (C=O), 170.3 (C=O), 170.1 (C=O), 170.0 (C=O), 169.8 (C=O), 169.6 (C=O), 169.1 (C=O), 139.0 ($CH=CH_2$), 114.3 ($CH=CH_2$), 101.1 (C-1'), 100.6 (C-1), 76.4 (C-4), 72.9 (C-3), 72.6 (C-5), 71.8 (C-2), 71.0 (C-3'), 70.7 (C-5'), 70.2 (octenyl OCH_2), 69.1 (C-2'), 66.6 (C-4'), 62.1 (C-6), 60.8 (C-6'), 33.7, 29.4, 28.84, 28.77, 25.7 ($5 \times$ octenyl CH_2); 20.9, 20.8, 20.71, 20.66, 20.65 (2C), 20.5 ppm ($7 \times OAc$); HRMS (ESI): m/z $[M+Na]^+$ calcd for $C_{34}H_{50}NaO_{18}$: 769.2889, found: 769.2880.

p-Tolyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1 \rightarrow 4)-6-O-benzyl-2-deoxy-2-phthalimido-1-thiol- β -D-glucopyranoside (10): A mixture of trichloroacetimidate **4** (1.80 g, 3.65 mmol), diol **6** (1.76 g 3.48 mmol) and powdered 4 Å molecular sieves was suspended in CH_2Cl_2 (40 mL) and stirred at RT for 1 h. The solution was cooled to -40 °C, and trimethylsilyl trifluoromethanesulfonate (TMSOTf; 63 μ L) was added drop wise. After stirring at -40 °C for 2 h, the mixture was allowed to warm to RT. Et_3N (1 mL) was added and the mixture was filtered through Celite. The filtrate was concentrated and subjected to flash chromatography (4:3 v/v hexane/EtOAc) to afford **10** as a white foam (2.21 g, 70%): $R_f=0.39$ (1:1 v/v hexane/EtOAc); $[\alpha]_D^{20} = +18.5$ ($c=0.9$, $CHCl_3$); 1H NMR (500 MHz, $CDCl_3$): $\delta = 7.88$ – 7.82 (m, 2H, Ar), 7.75–7.71 (m, 2H, Ar), 7.41–7.37 (m, 2H, Ar), 7.36–7.30 (m, 5H, Ar), 7.02–6.99 (m, 2H, Ar), 5.53 (d, $J = 10.5$ Hz, 1H, H-1), 5.31 (dd, $J = 3.5$, 1.0 Hz, 1H, H-4'), 5.18 (dd, $J = 10.5$, 8.0 Hz, 1H, H-2'), 4.93 (dd, $J = 10.5$, 3.5 Hz, 1H, H-3'), 4.68, 4.52 (ABq, $J = 12.0$ Hz, 2H, $2 \times OCH_2Ph$), 4.50 (d, $J = 8.0$ Hz, 1H, H-1'), 4.39 (dd, $J = 10.5$, 8.0 Hz, 1H, H-3), 4.20 (app t, $J = 10.5$ Hz, 1H, H-2), 4.05–4.00 (m, 3H, H-6a', H-6b', 3-OH), 3.89 (dt, $J = 6.5$,

1.0 Hz, 1H, H-5'), 3.76–3.64 (m, 4H, H-4, H-5, H-6a, H-6b), 2.27 (s, 3H, ArMe), 2.11 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.89 ppm (s, 3H, OAc); ^{13}C NMR (126 MHz, CDCl_3): δ = 170.4 (C=O), 170.1 (C=O), 169.9 (C=O), 169.2 (C=O), 168.2 (C=O), 167.5 (C=O), 138.3 (Ar), 138.2 (Ar), 134.1 (Ar), 133.7 (Ar), 131.9 (Ar), 131.8 (Ar), 129.6 (Ar), 128.5 (Ar), 127.84 (Ar), 127.81 (Ar), 123.6 (Ar), 123.3 (Ar), 101.6 (C-1'), 83.4 (C-1), 81.8 (C-4), 78.2 (C-5), 73.7 (OCH₂Ph), 71.2 (C-5'), 70.87 (C-3), 70.78 (C-3'), 68.7 (C-2'), 68.2 (C-6), 66.8 (C-4'), 61.4 (C-6'), 55.2 (C-2), 21.1, 20.7, 20.6, 20.5, 20.3 ppm (5C, 4×OAc, ArMe); HRMS (ESI): m/z $[M+\text{Na}]^+$ calcd for $\text{C}_{42}\text{H}_{45}\text{NNaO}_{15}\text{S}$: 858.2402, found: 858.2395.

7-Octen-1-yl 2,3,4-6-tetra-O-acetyl- β -D-galactopyranosyl-(1→4)-[2,3,4-tri-O-benzyl- α -L-fucopyranosyl-(1→3)]-6-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl-(1→3)-2,6-di-O-benzyl- β -D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (12): *N*-Bromosuccinimide (NBS; 287 mg, 1.62 mmol) was added to a solution of trisaccharide **2** (809 mg, 0.65 mmol) in acetone/H₂O (9:1 v/v, 7 mL) at 0 °C. After stirring at 0 °C for 0.5 h, saturated aq NaHCO₃ (2 mL) was added. The solution was concentrated, and the residue was dissolved in EtOAc (80 mL) and washed with H₂O and brine. The organic layer was dried over Na₂SO₄, filtered, concentrated and subjected to flash chromatography (4:5 v/v hexane/EtOAc) to afford **11** as a white solid (590 mg, 80%). A solution of **11** (455 mg, 0.39 mmol) in CH₂Cl₂ (4 mL) was treated with trichloroacetonitrile (0.28 mL, 2.75 mmol) and catalytic amount of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and stirred at RT for 4 h. Concentration and flash chromatography (1:1 v/v hexanes/EtOAc) afforded the trichloroacetimidate that was immediately used in the next step. The trichloroacetimidate (387 mg, 0.3 mmol), diol **3** (354 mg, 0.39 mmol) and powdered 4 Å molecular sieves were suspended in CH₂Cl₂ (4 mL) and stirred at RT for 1 h. The solution was then cooled to –30 °C, to which TMSOTf (14 μ L) was added. The mixture was allowed to warm to RT, and after stirring at –30 °C for 2 h, Et₃N (1 mL) was added, and the mixture was filtered through Celite. The filtrate was concentrated and subjected to flash chromatography (5:2 v/v hexane/EtOAc) to afford **12** as a white foam (390 mg, 49% over two steps): R_f = 0.46 (5:3 v/v hexane/EtOAc); $[\alpha]_D^{25}$ = +5.5 (c = 1.0, CHCl₃); ^1H NMR (600 MHz, CDCl₃): δ = 7.42–7.07 (m, 45H, Ar), 7.01 (d, J = 7.2 Hz, 2H, Ar), 6.79 (d, J = 7.2 Hz, 2H, Ar), 5.78 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H, CH=CH₂), 5.32 (d, J = 8.5 Hz, 1H, H-1''), 5.25 (dd, J = 3.5, 0.8 Hz, 1H, H-4'''), 5.03 (dd, J = 10.4, 8.2 Hz, 1H, H-2'''), 4.97 (dq, J = 17.1, 1.8 Hz, 1H, CH=CH₂), 4.93–4.89 (m, 2H, CH=CH₂, OCH₂Ph), 4.84–4.78 (m, 4H, H-1''', H-3''', 2 × OCH₂Ph), 4.74–4.65 (m, 5H, H-1''', H-3'', 3 × OCH₂Ph), 4.60–4.53 (m, 4H, H-5''', 3 × OCH₂Ph), 4.48–4.42 (m, 4H, H-2'', 3 × OCH₂Ph), 4.33 (A of ABq, J = 12.2 Hz, 2H, 2 × OCH₂Ph), 4.30–4.25 (m, 2H, H-1', OCH₂Ph), 4.21–4.17 (m, 3H, H-1, 2 × OCH₂Ph), 4.16–4.12 (m, 3H, H-4', H-6a'', OCH₂Ph), 4.05 (br s, 1H, H-4'), 3.95 (dd, J = 10.9, 5.9 Hz, 1H, H-6b''), 3.85–3.81 (m, 4H, H-3''', H-4, H-6a'', octenyl OCH₂), 3.75 (dd, J = 12.2 Hz, 1H, H-2'''), 3.71–3.68 (m, 2H, H-6b'', H-6a'), 3.61–3.58 (m, 3H, H-4''', H-5'', H-5'''), 3.49 (dd, J = 9.6, 5.6 Hz, 1H, H-6b'), 3.42 (dd, J = 10.8 Hz, 4.2 Hz, 1H, H-6a), 3.42–3.35 (m, 5H, H-2', H-3', H-3, H-5', octenyl OCH₂), 3.32–3.27 (m, 2H, H-2, H-6b), 2.96 (ddd, J = 9.6, 4.2, 1.8 Hz, 1H, H-5), 2.71 (br s, 1H, 4'-OH), 2.03–1.99 (m, 8H, 2 × OAc, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.96 (s, 3H, OAc), 1.85 (s, 3H, OAc), 1.62–1.55 (m, 2H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.37–1.26 (m, 6H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.19 ppm (d, J = 6.6 Hz, 3H, H-6'''); ^{13}C NMR (126 MHz, CDCl₃): δ = 170.1 (C=O), 170.0 (C=O), 169.9 (C=O), 168.7 (C=O), 139.10 (Ar), 139.06 (CH=CH₂), 138.8 (Ar), 138.75 (Ar), 138.65 (Ar), 138.57 (Ar), 138.56 (Ar), 138.4 (Ar), 138.2 (Ar), 137.6 (Ar), 133.9 (Ar), 131.3 (Ar), 128.7 (Ar), 128.4 (Ar), 128.27 (Ar), 128.25 (2C, Ar), 128.16 (Ar), 128.13 (Ar), 128.11 (Ar), 128.02 (Ar), 128.0 (Ar), 127.85

(Ar), 127.83 (Ar), 127.75 (Ar), 127.5 (Ar), 127.4 (Ar), 127.2 (2C, Ar), 127.1 (Ar), 127.0 (Ar), 126.6 (Ar), 126.3 (Ar), 123.3 (Ar), 114.2 (CH=CH₂), 103.5 (C-1), 102.0 (C-1'), 99.6 (C-1'''), 99.0 (C-1''), 97.6 (C-1'''), 83.5 (C-3), 82.9 (C-2'), 81.8 (C-2), 79.7 (C-3'''), 78.1 (C-3'), 77.2 (C-4'''), 75.9 (C-4), 75.4 (OCH₂Ph), 75.3 (C-4''), 75.1 (C-5''), 74.9 (OCH₂Ph), 74.75, 74.72 (C-2'''), C-5), 74.21, 74.16, 73.8, 73.4, 73.0, 72.9 (6 × OCH₂Ph), 72.64, 72.60 (C-3'', C-5'), 72.4 (OCH₂Ph), 71.0 (C-3'''), 70.5 (C-5'''), 69.9 (octenyl OCH₂), 69.1 (C-2'''), 68.5, 68.0, 67.9 (C-6, C-6', C-6''), 67.5 (C-4'), 66.8 (C-4''), 66.6 (C-5'''), 60.3 (C-6'''), 56.2 (C-2''), 33.7, 29.7, 28.9, 28.8, 26.0 (5 × octenyl CH₂), 20.7, 20.62, 20.56, 20.5 (4 × OAc), 16.8 ppm (C-6'''); HRMS (ESI): m/z $[M+\text{Na}]^+$ calcd for $\text{C}_{117}\text{H}_{131}\text{NNaO}_{30}$: 2052.8648, found: 2052.8612.

7-Octen-1-yl 2,3,4-6-tetra-O-acetyl- β -D-galactopyranosyl-(1→4)-[2,3,4-tri-O-benzyl- α -L-fucopyranosyl-(1→3)]-6-O-benzyl-2-deoxy-2-phthalimido- β -D-glucopyranosyl-(1→3)-4-O-acetyl-2,6-di-O-benzyl- β -D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (12): A solution of **12** (10 mg, 4.9 μ mol) in pyridine (1 mL) and Ac₂O (0.5 mL, 5.3 mmol) was stirred overnight at RT, concentrated in vacuo, and the residue subjected to flash chromatography (5:2 v/v hexane/EtOAc) to afford **12'** as a white foam (9.5 mg, 93%): R_f = 0.45 (5:3 v/v hexane/EtOAc); $[\alpha]_D^{25}$ = +4.2 (c = 0.8, CHCl₃); ^1H NMR (600 MHz, CDCl₃): δ = 7.45–7.09 (m, 45H, Ar), 7.02–7.01 (m, 2H, Ar), 6.87–6.85 (m, 2H, Ar), 5.80 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H, CH=CH₂), 5.46 (dd, J = 3.6, 0.6 Hz, 1H, H-4'), 5.28 (dd, J = 3.6, 1.0 Hz, 1H, H-4''), 5.26 (d, J = 8.2 Hz, 1H, H-1'), 5.04 (dd, J = 10.4, 8.2 Hz, 1H, H-2'''), 5.00–4.97 (m, 1H, CH=CH₂), 4.95–4.92 (m, 2H, CH=CH₂, OCH₂Ph), 4.90 (A of ABq, J = 10.5 Hz, 1H, OCH₂Ph), 4.86–4.83 (m, 3H, H-1''', H-3''', OCH₂Ph), 4.81, 4.57 (ABq, J = 11.8 Hz, 2H, 2 × OCH₂Ph), 4.78 (d, J = 3.6 Hz, 1H, H-1'''), 4.75 (dd, J = 10.2, 9.0 Hz, 1H, H-3''), 4.69–4.63 (m, 5H, H-5''', 4 × OCH₂Ph), 4.55 (A of ABq, J = 11.7 Hz, 1H, OCH₂Ph), 4.47 (A of ABq, J = 12.2 Hz, 1H, OCH₂Ph), 4.43–4.40 (m, 3H, H-2'', 2 × OCH₂Ph), 4.30–4.26 (m, 3H, H-1', 2 × OCH₂Ph), 4.23–4.15 (m, 5H, H-1, H-4', H-6a''', 2 × OCH₂Ph), 4.00 (A of ABq, J = 11.8 Hz, 1H, OCH₂Ph), 3.97 (dd, J = 10.8, 5.7 Hz, 1H, H-6b'''), 3.93 (dd, J = 5.4, 3.0 Hz, 1H, H-6a''), 3.89–3.83 (m, 4H, H-3''', H-4, H-6b'', octenyl OCH₂), 3.77 (dd, J = 10.2, 3.7 Hz, 1H, H-2'''), 3.63–3.60 (m, 2H, H-4''', H-5'''), 3.56–3.52 (m, 2H, H-3', H-5'), 3.47–3.41 (m, 3H, H-5', H-6a, octenyl OCH₂), 3.38 (m, 2H, H-3, H-6a'), 3.33–3.29 (m, 4H, H-2, H-2', H-6b, H-6b'), 2.98–2.96 (ddd, J = 9.6, 3.6, 1.8 Hz, 1H, H-5), 2.09 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03–2.02 (m, 5H, OAc, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.97 (s, 3H, OAc), 1.85 (s, 3H, OAc), 1.63–1.59 (m, 2H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.39–1.29 (m, 6H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.21 ppm (d, J = 6.0 Hz, 3H, C-6'''); ^{13}C NMR (126 MHz; CDCl₃): δ = 170.02 (C=O), 170.01 (C=O), 169.96 (C=O), 169.86 (C=O), 168.8 (C=O), 139.12 (Ar), 139.05 (CH=CH₂), 138.89 (Ar), 138.69 (Ar), 138.68 (Ar), 138.4 (Ar), 138.28 (Ar), 138.27 (Ar), 138.23 (Ar), 138.19 (Ar), 133.8 (Ar), 131.3 (Ar), 128.5 (Ar), 128.31 (Ar), 128.26 (Ar), 128.15 (Ar), 128.13 (Ar), 128.09 (Ar), 128.01 (Ar), 127.94 (Ar), 127.92 (Ar), 127.90 (Ar), 127.83 (Ar), 127.79 (2C, Ar), 127.78 (Ar), 127.53 (Ar), 127.48 (Ar), 127.41 (Ar), 127.3 (Ar), 127.13 (Ar), 127.11 (Ar), 127.0 (Ar), 126.9 (Ar), 126.4 (Ar), 123.3 (Ar), 114.2 (CH=CH₂), 103.6 (C-1), 102.0 (C-1'), 99.5 (C-1''), 99.1 (C-1'), 97.2 (C-1'''), 82.6 (C-3), 81.6, 78.84, 78.79 (C-2, C-2', C-3'), 79.7 (C-3'''), 77.2 (C-4'''), 75.7 (C-4), 75.4 (C-5''), 75.2 (OCH₂Ph), 74.96 (C-4''), 74.92 (OCH₂Ph), 74.7, 74.5 (C-5, C-2'''), 74.20, 74.15, 73.6, 73.50, 73.0, 72.7 (6 × OCH₂Ph), 72.6 (C-5'), 72.4 (OCH₂Ph), 72.0 (C-3''), 71.0 (C-3'''), 70.4 (C-5'''), 69.94 (C-4'), 69.90 (octenyl OCH₂), 69.0 (C-2''), 68.3, 67.7, 67.6 (C-6, C-6', C-6''), 66.8 (C-4''), 66.4 (C-5'''), 60.2 (C-6'''), 56.6 (C-2''), 33.7, 29.7, 28.9, 28.8, 26.0 (5 × octenyl CH₂), 20.83, 20.75, 20.64, 20.56, 20.54 (5 × OAc), 16.7 ppm (C-6'''); HRMS (ESI): m/z $[M+\text{Na}]^+$ calcd for $\text{C}_{119}\text{H}_{133}\text{NNaO}_{31}$: 2094.8754, found: 2094.8751.

7-Octen-1-yl β -D-galactopyranosyl-(1 \rightarrow 4)-[2,3,4-tri-O-benzyl- α -L-fucopyranosyl-(1 \rightarrow 3)]-6-O-benzyl-2-deoxy-2-acetamido- β -D-glucopyranosyl-(1 \rightarrow 3)-2,6-di-O-benzyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (13): A solution of pentasaccharide **12** (352 mg, 0.17 mmol) in *n*-butanol (15 mL) was treated with ethylenediamine (3 mL, 44.9 mmol), followed by stirring at 100 °C for 20 h. The solution was concentrated in vacuo to dryness. The crude residue was dissolved in CH₂Cl₂/MeOH (1:2 v/v, 6 mL), to which Ac₂O (1 mL) and Et₃N (1 mL) were added. After stirring at RT for 5 h, the solution was concentrated, and the residue subjected to flash chromatography (3:2 v/v toluene/acetone). Further purification by C₁₈ chromatography (1:1 v/v MeOH/H₂O \rightarrow MeOH) afforded **13** as a white foam (255 mg, 83%). *R*_f=0.51 (4:5 v/v toluene/acetone); [α]_D=−19.6 (*c*=1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃): δ =7.42–7.19 (m, 45H), 5.80 (ddt, *J*=17.0, 10.3, 6.7 Hz, 1H, CH=CH₂), 5.67 (d, *J*=7.2 Hz, 1H, NH), 5.16 (d, *J*=7.5 Hz, 1H, H-1''), 5.05 (d, *J*=3.6 Hz, 1H, H-1'''), 5.00–4.97 (m, 2H, CH=CH₂, OCH₂Ph), 4.94–4.87 (m, 4H, CH=CH₂, 3 \times OCH₂Ph), 4.74–4.70 (m, 4H, 4 \times OCH₂Ph), 4.66–4.63 (m, 2H, 2 \times OCH₂Ph), 4.60–4.55 (m, 3H, 3 \times OCH₂Ph), 4.53, 4.47 (ABq, *J*=12.2 Hz, 2H, 2 \times OCH₂Ph), 4.44–4.38 (m, 4H, H-1', H-1''', 2 \times OCH₂Ph), 4.35–4.32 (m, 2H, H-1, H-3''), 4.29 (A of ABq, *J*=12.0 Hz, 1H, OCH₂Ph), 4.12–4.08 (m, 2H, H-5''', OH), 4.05–4.01 (m, 3H, H-2'''), 3.94–3.86 (m, 5H, H-3''', H-6a'', octenyl OCH₂), 3.78–3.76 (m, 1H, H-4''), 3.74–3.65 (m, 6H, H-6b''), 3.62–3.58 (m, 2H, H-4'''), 3.54–3.46 (m, 7H, H-2', H-2'', H-3, H-3', octenyl OCH₂), 3.44–3.33 (m, 4H, H-2, H-2''), 3.30–3.27 (m, 1H), 2.99–2.97 (m, 2H, OH), 2.72 (br s, 1H, OH), 2.05–2.01 (m, 2H, OCH₂CH₂-(CH₂)₃CH₂CH=CH₂), 1.64–1.62 (m, 2H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.40–1.32 (m, 9H, NHAc, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.11 ppm (d, *J*=6.0 Hz, 3H, H-6'''); ¹³C NMR (126 MHz, CDCl₃): δ =170.9 (C=O), 139.2 (Ar), 139.1 (CH=CH₂), 139.0 (Ar), 138.7 (Ar), 138.44 (Ar), 138.43 (Ar), 138.38 (Ar), 138.2 (Ar), 137.5 (Ar), 128.6 (Ar), 128.51 (Ar), 128.47 (Ar), 128.31 (Ar), 128.27 (Ar), 128.25 (Ar), 128.20 (Ar), 128.1 (Ar), 128.04 (2C, Ar), 128.01 (Ar), 127.91 (Ar), 127.86 (Ar), 127.71 (Ar), 127.67 (Ar), 127.66 (Ar), 127.63 (Ar), 127.53 (Ar), 127.51 (Ar), 127.46 (Ar), 127.39 (Ar), 127.37 (Ar), 127.2 (Ar), 114.2 (CH=CH₂), 103.6 (C-1), 102.2 (C-1'), 100.1 (C-1'''), 99.7 (C-1''), 98.0 (C-1'''), 82.9 (C-3), 82.3 (C-2'), 81.9 (C-2), 79.4, 79.0 (C-3', C-3'''), 77.2 (C-4'''), 76.6, 76.5, 76.4, 76.0, 75.3 (OCH₂Ph), 75.14, 75.08, 74.95 (OCH₂Ph), 74.93 (OCH₂Ph), 74.8, 74.7 (OCH₂Ph), 74.1 (OCH₂Ph), 73.7, 73.6, 73.4, 73.2 (3 \times OCH₂Ph), 72.9, 72.4 (OCH₂Ph), 71.7, 70.0, 69.9, 68.9, 68.4 (C-6, C-6', C-6'', octenyl OCH₂), 69.3, 67.9, 67.5 (C-5'''), 63.0 (C-6'''), 57.5 (C-2''), 33.7, 29.7, 28.95, 28.86, 26.0 (5 \times octenyl CH₂), 22.9 (NHAc), 16.7 ppm (C-6'''); HRMS (ESI): *m/z* [*M*+Na]⁺ calcd for C₁₀₃H₁₂₃NNaO₂₅: 1796.8276, found: 1796.8254.

7-Octen-1-yl β -D-galactopyranosyl-(1 \rightarrow 4)-[α -L-fucopyranosyl-(1 \rightarrow 3)]-2-acetamido-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside (14): Sodium was added to freshly collected liquid ammonia (~8 mL) at −78 °C until the blue colour of the solution persisted. A solution of **13** (144 mg, 0.73 mmol) in THF (4 mL) and MeOH (30 μ L) was added drop wise at −78 °C. After 2 h, MeOH (5 mL) was added and the solution was concentrated in vacuo to dryness. The residue was dissolved in MeOH (30 mL), neutralized with Amberlite IR120 H⁺ ion-exchange resin, filtered and concentrated. The crude residue was purified by C₁₈ chromatography using gradient elution (H₂O \rightarrow 3:7 v/v MeOH/H₂O) to give **14** as a white solid (76 mg, 97%). [α]_D=−45.6 (*c*=0.9, MeOH); ¹H NMR (600 MHz, D₂O): δ =5.91 (ddt, *J*=17.2, 10.4, 6.7 Hz, 1H, CH=CH₂), 5.11 (d, *J*=4.0 Hz, 1H, H-1'''), 5.06–5.02 (m, 1H, CH=CH₂), 4.97–4.95 (m, 1H, CH=CH₂), 4.82 (q, *J*=6.7 Hz, 1H, H-5'''), 4.70 (d, *J*=8.3 Hz, 1H, H-1''), 4.46 (d, *J*=7.8 Hz, 1H, H-1'''), 4.45 (d, *J*=7.8 Hz, 1H, H-1'), 4.42 (d, *J*=7.8 Hz, 1H, H-1), 4.14 (d, *J*=3.5 Hz, 1H), 3.96–3.84 (m, 9H), 3.79–3.55 (m, 17H), 3.48 (dd, *J*=9.8, 7.8 Hz,

H-2'), 3.28 (dd, *J*=9.6, 7.8 Hz, 1H, H-2''), 2.07–2.03 (m, 2H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 2.01 (s, 3H, NHAc), 1.63–1.59 (m, 2H, OCH₂CH₂(CH₂)₃CH₂CH=CH₂), 1.41–1.30 (m, 6H, OCH₂CH₂-(CH₂)₃CH₂CH=CH₂), 1.16 ppm (d, *J*=6.6 Hz, 3H, H-6'''); ¹³C NMR (126 MHz, D₂O): δ =175.7 (C=O), 141.3 (CH=CH₂), 115.0 (CH=CH₂), 103.9 (C-1), 103.5, 103.0, 102.8 (C-1', C-1'', C-1'''), 99.6 (C-1'''), 83.1, 79.4, 76.1, 75.9, 75.8, 75.7 (2C), 75.4, 74.1, 73.8, 73.5, 72.9, 72.0, 71.7, 70.9, 70.2, 69.33, 69.28, 68.7, 67.7 (C-5'''), 62.5, 61.9, 61.1, 60.6 (C-6, C-6', C-6'', C-6'''), 57.0 (C-2''), 34.0 (octenyl CH₂), 29.6 (octenyl CH₂), 29.0 (2C, octenyl CH₂), 25.8 (octenyl CH₂), 23.2 (NHAc), 16.3 ppm (C-6'''); HRMS (ESI): *m/z* [*M*+Na]⁺ calcd for C₄₀H₆₉NNaO₂₅: 986.4051, found: 986.4047.

8-[(2-Aminoethyl)thiol]-1-octyl β -D-galactopyranosyl-(1 \rightarrow 4)-[α -L-fucopyranosyl-(1 \rightarrow 3)]-2-acetamido-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside (15):

Compound **14** (38 mg, 0.039 mmol) and cysteamine hydrochloride (44 mg, 0.39 mmol) were dissolved in dry MeOH (0.5 mL) in a quartz tube. The solution was degassed and the tube was filled with argon. After irradiation with UV light for 2.5 h, the solution was concentrated and subjected to C₁₈ chromatography using gradient elution (0.5% aq AcOH \rightarrow 3:7 v/v MeOH/0.5% aq AcOH) to afford the corresponding amine salt **15** (42 mg, quantitative). [α]_D=−41.1 (*c*=0.9, MeOH); ¹H NMR (600 MHz, D₂O): δ =5.11 (d, *J*=3.9 Hz, 1H, H-1'''), 4.83–4.80 (m, 1H, H-5'''), 4.70 (d, *J*=8.4 Hz, 1H, H-1''), 4.46 (d, *J*=7.8 Hz, 1H, H-1'''), 4.45 (d, *J*=7.8 Hz, 1H, H-1'), 4.42 (d, *J*=7.8 Hz, 1H, H-1), 4.14 (d, *J*=2.9 Hz, 1H), 3.96–3.84 (m, 9H), 3.79–3.55 (m, 17H), 3.48 (dd, *J*=9.6, 7.8 Hz, 1H, H-2'), 3.29–3.26 (m, 1H, H-2''), 3.20 (t, *J*=6.7 Hz, 2H, SCH₂CH₂N), 2.83 (t, *J*=6.7 Hz, 2H, SCH₂CH₂N), 2.58 (t, *J*=7.3 Hz, 2H, SCH₂(CH₂)₆CH₂O), 2.01 (s, 3H, NHAc), 1.63–1.56 (m, 4H, OCH₂CH₂(CH₂)₄CH₂CH₂S), 1.38–1.31 (m, 8H, OCH₂CH₂(CH₂)₄CH₂CH₂S), 1.16 ppm (d, *J*=6.6 Hz, 3H, H-6'''); ¹³C NMR (126 MHz, D₂O): δ =175.7 (C=O), 103.9 (C-1), 103.5, 103.0, 102.8 (C-1', C-1'', C-1'''), 99.6 (C-1'''), 83.1, 79.4, 76.1, 75.90, 75.86, 75.7 (2C), 75.5, 74.1, 73.8, 73.5, 72.9, 72.0, 71.7, 70.9, 70.2, 69.34, 69.27, 68.7, 67.7 (C-5'''), 62.5, 61.9, 61.1, 60.6 (C-6, C-6', C-6'', C-6'''), 57.0 (C-2''), 39.4 (SCH₂CH₂N), 31.7 (SCH₂(CH₂)₆CH₂O), 29.7 (SCH₂(CH₂)₆CH₂O), 29.5 (SCH₂CH₂N), 29.3, 29.1(2C), 28.8, 25.9 (5 \times SCH₂(CH₂)₆CH₂O), 23.2 (NHAc), 16.3 ppm (C-6'''); HRMS (ESI): *m/z* [*M*+H]⁺ calcd for C₄₂H₇₇N₂O₂₅S: 1041.4531, found: 1041.4517.

Preparation of HSA conjugate: Compound **1** (1.5 mg) was dissolved in DMF (15 μ L) and injected into a solution of human serum albumin (HSA; 1.5 mg) in phosphate buffer (0.3 mL, pH 7.5). The reaction was left at RT for one day, and the mixture was dialyzed against deionized H₂O (5 \times 4 L). A white solid was obtained after lyophilization. The degree of incorporation of the pentasaccharide into the glycoconjugate was determined to be 21 by MALDI-TOF MS.

Acknowledgement

Funding for this work was obtained via a Canadian Institutes of Health Research (CIHR) team grant (RMF 92091), a Natural Sciences and Engineering Research Council of Canada (NSERC)/CIHR Collaborative Health Research Projects (CHRP) grant (CHRPJ350946-08) and the Alberta Glycomics Centre (Canada). Alberta Innovates—Technology Futures is gratefully acknowledged for a scholarship to JZ.

Keywords: activated esters · immunomodulatory glycans · lacto-*N*-fucopentaose III (LNFP III) · regioselective glycosylation · oligosaccharides

- [1] A. I. Ko, U. C. Dräger, D. A. Harn, *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 4159–4163.
- [2] B. Stahl, S. Thurl, J. R. Zeng, M. Karas, F. Hillenkamp, M. Steup, G. Sawatzki, *Anal. Biochem.* **1994**, *223*, 218–226.
- [3] P. Dutta, D. A. Hullett, D. A. Roenneburg, J. R. Torrealba, H. W. Sollinger, D. A. Harn, W. J. Burlingham, *Transplantation* **2010**, *90*, 1071–1078.
- [4] G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser, L. Carter, V. Ling, M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, T. Honjo, *J. Exp. Med.* **2000**, *192*, 1027–1034.
- [5] X. Fan, A. Ang, S. M. Pollock-BarZiv, A. I. Dipchand, P. Ruiz, G. Wilson, J. L. Platt, L. J. West, *Nat. Med.* **2004**, *10*, 1227–1233.
- [6] A. M. Slaney, V. A. Wright, P. J. Meloncelli, K. D. Harris, L. J. West, T. L. Lowary, J. M. Buriak, *ACS Appl. Mater. Interfaces* **2011**, *3*, 1601–1612.
- [7] Y.-M. Zhang, J. Esnault, J.-M. Mallet, P. Sinaÿ, *J. Carbohydr. Chem.* **1999**, *18*, 419–427.
- [8] Y. Zhang, D. Dong, H. Qu, M. Sollogoub, Y. Zhang, *Eur. J. Org. Chem.* **2011**, *2011*, 7133–7139.
- [9] C.-S. Chao, C.-W. Li, M.-C. Chen, S.-S. Chang, K.-K. T. Mong, *Chem. Eur. J.* **2009**, *15*, 10972–10982.
- [10] Z. Zhang, I. R. Ollmann, X.-S. Ye, R. Wischnat, T. Baasov, C.-H. Wong, *J. Am. Chem. Soc.* **1999**, *121*, 734–753.
- [11] R. Johnsson, D. Olsson, U. Ellervik, *J. Org. Chem.* **2008**, *73*, 5226–5232.
- [12] H. Cheng, X. Cao, M. Xian, L. Fang, T. B. Cai, J. J. Ji, J. B. Tunac, D. Sun, P. G. Wang, *J. Med. Chem.* **2005**, *48*, 645–652.
- [13] U. Ellervik, G. Magnusson, *J. Org. Chem.* **1998**, *63*, 9314–9322.
- [14] M. Guillemineau, F.-I. Auzanneau, *Carbohydr. Res.* **2012**, *357*, 132–138.
- [15] K. Bock, C. Pedersen, *J. Chem. Soc. Perkin Trans. 2* **1974**, 293.
- [16] J. D. C. Codée, R. E. J. N. Litjens, R. den Heeten, H. S. Overkleeft, J. H. van Boom, G. A. van der Marel, *Org. Lett.* **2003**, *5*, 1519–1522.
- [17] A. Dondoni, A. Massi, P. Nanni, A. Roda, *Chem. Eur. J.* **2009**, *15*, 11444–11449.
- [18] X. Wu, C.-C. Ling, D. R. Bundle, *Org. Lett.* **2004**, *6*, 4407–4410.

Received: May 15, 2013

Published online on July 11, 2013